The Northern Irish contract development and manufacturing organisation’s new 100,000sq ft facility increases the company’s existing capabilities.
Northern Ireland-based pharmaceutical development and manufacturing services company Almac has opened a new £65 million commercial manufacturing facility for Almac Pharma Services at its global headquarters in Craigavon.
The 100,000 sq ft facility increases the company’s existing capabilities in commercial manufacture of oral dose treatments for a variety of therapeutic areas.
Construction of the building was completed late last year and following the successful completion of validation activities, manufacture of GMP batches will start in the second half of March.
The facility has been designed so that partner companies can install custom and dedicated technology tailored to their individual and emerging pipeline needs.
“The new facility not only expands our range of capabilities but also reinforces our position as an industry leader in pharmaceutical development and commercial manufacturing with an ability to tailor our services to suit individual products,” said John McQuaid, the company’s president and managing director.
In a statement, the company said that it had initially committed to £250 million in capital investment and a growth of 1,800 new jobs across the group globally in 2022. Since then, Almac has increased its projected investment figure to more than £400 million.
